Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy) benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats?

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 1, 2008, Pages 41-50

  Conway, James G ^a,c   Pink, Heather ^a   Bergquist, Mandy L ^a   Han, Bajin ^a   Depee, Scott ^a   Tadepalli, Sarva ^a   Lin, Peiyuan ^a   Crumrine, R Christian ^a   Binz, Jane ^a   Clark, Richard L ^b   Selph, Jeffrey L ^a   Stimpson, Stephen A ^a   Hutchins, Jeff T ^a   Chamberlain, Stanley D ^a   Brodie, Thomas A ^a  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [3 METHOXY 4 [(4 METHOXYBENZYL)OXY]BENZYL]PYRIMIDINE 2,4 DIAMINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BACTERIUM LIPOPOLYSACCHARIDE; CELLULAR HOMOLOG OF THE V FMS ONCOGENE PRODUCT OF THE SUSAN MCDONOUGH STRAIN OF FELINE SARCOMA VIRUS KINASE INHIBITOR; COLONY STIMULATING FACTOR 1; GW 2580; PEPTIDOGLYCAN POLYSACCHARIDE; PHOSPHOTRANSFERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKLE SWELLING; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; BONE DESTRUCTION; BONE MINERAL; BONE RADIOGRAPHY; CHRONIC DRUG ADMINISTRATION; CLINICAL CHEMISTRY; DRUG EFFECT; DRUG INHIBITION; DRUG SELECTIVITY; IC 50; IN VITRO STUDY; LIMB SWELLING; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RAT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; ANISOLES; ARTHRITIS, EXPERIMENTAL; CELLS, CULTURED; HUMANS; MALE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, INBRED LEW; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SARCOMA VIRUSES, FELINE;

EID: 45749136367     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.129429     Document Type: Article

References (39)

1. Abd AA, Savage NW, Halliday WJ, and Hume DA (1991) The role of macrophages in experimental arthritis induced by Streptococcus agalactiae sonicate: actions of macrophage colony-stimulating factor (CSF-1) and other macrophage modulating agents. Lymphokine Cytokine Res 10:43-50.
2. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei R, Li J, Guo J, Bousquet PF, Ghoreseishi-Haack NS, et al. (2006) Preclinical activity of ABL-869, a multitarget receptor kinase inhibitor. Mol Cancer Ther 5:995-1006.
3. Ando W, Hashimoto J, Nampel A, Tsuboi H, Tateishi K, Ono T, Nakamura N, Ochi T, and Yoshikawa H (2006) Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J Bone Miner Metab 24:274-282.
4. Bischof RJ, Zafiropoulos D, Hamilton JA, and Campbell IK (2000) Exacerbation of acute inflammatory arthritis by the colony-stimulating factors CSF-1 and granulocyte macrophage (GM)-CSF: evidence of macrophage infiltration and local proliferation. Clin Exp Immunol 119:361-367.
5. Bock SN, Cameron RB, Kragel P, Mule JJ, and Rosenberg SA (1991) Biological and antitumor effects of recombinant human macrophage colony-stimulation factor in mice. Cancer Res 51:2649-2654.
6. Boone L, Meyer D, Cusnick P, Ennlate D, Provencher Bolliger A, Everds N, Meador V, Elliot G, Honor D, Bounous D, et al. (2005) Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol 34:182-188.
7. Campbell IK, Rich MJ, Bischof RJ, and Hamilton JA (2000) The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leukocyte Biol 68:144-150.
8. Chang MY, Stanley ER, Khalili H, Chisholm O, and Pollard JW (1995) Osteopetrotic (op/op) mice deficient in macrophages have the ability to mount a normal T-cell-dependent immune response. Cell Immunol 162:146-152.
9. Chang YH, Pearson CM, and Abe C (1980) Adjuvant polyarthritis. IV. Induction by a synthetic adjuvant: immunologic, histopathologic and other studies. Arthritis Rheum 23:62-71.
10. Chitu V and Stanley ER (2006) Colony stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 18:39-48.
11. Clark RL, Cuttino JT Jr, Anderle SK, Cromartie WJ, and Swab JH (1979) Radiologic analysis of arthritis in rats after systemic injection of streptococcal cell walls. Arthritis Rheum 22:25-35.
12. Conway JG, Andrews RC, Beaudet B, Bickett DM, Boncek V, Brodie TA, Clark RL, Crumrine RC, Leenitzer MA, McDougald DL, et al. (2001) Inhibition of tumor necrosis factor-α production and arthritis in the rat by GW3333, a dual inhibitor or TNF-α-converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther 298:900-908.
13. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM, et al. (2005) Inhibition of colony stimulating factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A 102:16078-16083.
14. Cupp JS, Miller MA, Montgomery KD, Nielson TO, O'Connell JX, Huntsman D, van de Rijn M, Gilks CB, and West RB (2007) Translocation and expression of CSF-1 in pigmented synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol 31:970-976.
15. Dai X, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, and Stanley ER (2002) Targeted disruption of the mouse colony-stimulating factor-1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor frequencies, and reproductive effects. Blood 99:111-120.
16. Fabian MA, Biggs WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336.
17. Guleria I and Pollard JW (2001) Aberrant macrophage and neutrophil population dynamics and impaired Th1 response to Listeria monocytogenes in colony-stimulating factor-1-deficient mice. Infect Immun 69:1795-1807.
18. Jiang S, Naito M, Kaizu C, Kuwata K, Hasegawa G, Mukaida N, and Shultz LD (2000) Lipopolysaccharide-induced cytokine and receptor expression and neutrophil infiltration in the liver of osteopetrosis (op/op) mutant mice. Liver 20:465-474.
19. Kawaji H, Yokomura K, Kikuchi K, Somoto Y, and Shira Y (1995) Macrophage colony-stimulating factor in patients with rheumatoid arthritis. Nippon Ika Daigaku Zasshi 62:260-270.
20. Kitaura H, Zhou P, Kim H, Novack DV, Ross FP, and Teitelbaum SL (2005) M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 115:3418-3427.
21. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, et al. (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast bone metastasis model. Clin Exp Metastasis 20:757-766.
22. Nishioji K, Okanoue T, Mori T, Sakamoto S, and Itoh Y (1999) Experimental liver injury induced by Propionibacterium acnes and lipopolysaccharide in macrophage colony stimulating factor-deficient osteopetrotic (op/op) mice. Dig Dis Sci 44:1975-1984.
23. Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shiduya M, Yoneda T, and Isoe T (2006) A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther 5:2634-2643.
24. Owen RT (1980) Adjuvant induced polyarthritis-an overview. Methods Find Exp Clin Pharmacol 2:199-204.
25. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, et al. (2006) Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116:2633-2642.
26. Pearson CM and Wood FD (1963) Studies of polyarthritis and other lesions induced in rats by the injection of mycobacterial adjuvant. VII. Pathologic details of the arthritis and spondylitis. Am J Med 42:73-94.
27. Robinson WH and Paniagua RT (2007) inventors; University of Leland Stanford Jr., assignee. Method of treating inflammatory diseases using tyrosine kinase inhibitors. World Patent WO2007143146 A2. 2007 Dec 13.
28. Sacca R, Stanley ER, Sherr CJ, and Rettenmier CW (1986) Specific binding of the mononuclear phagocyte colony-stimulating factor CSF-1 to the product of the v-fms oncogene. Proc Natl Acad Sci U S A 83:3331-3335.
29. Sarma U and Flanagan AM (1996) Macrophage colony-stimulating factor induces substantial osteoclast generation and bone resorption in human bone marrow cultures. Blood 88:2531-2540.
30. Schwab JH, Brown RR, Anderle SR, and Schlievert PM (1993) Superantigen can reactivate bacterial cell-wall-induced arthritis. J Immunol 150:4151-4159.
31. Seitz M, Loetscher P, Fey MF, and Tobler A (1994) Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol 33:613-619.
32. Shewchuk LM, Hassell AM, Holmes WD, Veal JM, Emmerson HK, Musso DL, Chamberlain SD, and Peckham GE (2004) inventors; GlaxoSmithKline Inc., assignee. Co-crystal structure of liganded inhibitors of colony-stimulating factor 1 receptor kinase in treatment of disease. U.S. Patent 2004002145 A1. 2004 Jan 1.
33. Stokes ME, Davis CS, and Koch GG (2000) Sets of 2 x r and s x 2 tables, in Categorical Data Analysis using the SAS System, 2nd ed., pp 67-90, SAS Institute, Cary, NC.
34. Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, and Suda T (1993) Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 91:257-263.
35. Weir EC, Lowik CW, Paliwal I, and Insogna KL (1996) Colony stimulating factor-1 plays a role in osteoclast formation and function in bone resorption induced by parathyroid and parathyroid hormone-related protein. J Bone Miner Res 11:1474-1481.
36. Wiktor-Jedrzejczak W, Ansari AA, Szperi M, and Urbanowska E (1992a) Distinct in vivo functions of two macrophage subpopulations as evidenced by studies using macrophage-deficient op/op mice. Eur J Immunol 22:1951-1954.
37. Wiktor-Jedrzejczak W, Bartocci A, Rerrante AW Jr, Ahmed-Ansari A, Sell KW, Pollard JW, and Stanley ER (1990) Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A 87:4828-4832.
38. Wiktor-Jedrzejczak W, Dzwigala B, Szperi M, Maruszynski M, Urbanowska E, and Szwech P (1996) Colony-stimulation factor 1-dependent resident macrophages play a regulatory role in fighting Escherichia Coli fecal peritonitis. Infect Immun 64:1577-1581.
39. Wiktor-Jedrzejczak W, Ratajczak MZ, Ptasznik A, Sell K, Ahmed-Ansari A, and Ostertag W (1992b) CSF-1 deficiency in the op/op mouse has differential effects on macrophage populations in differentiation stages. Exp Hematol 20:1004-1010.